The $16 billion in disaster aid covers crop losses due to natural disasters from 2023 and 2024. It's the largest chunk of the ...

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the most promising stocks according to Wall Street analysts. On June 24, ...

Syndax now has two approved therapies, but the share price remains under pressure despite these milestones. See why SNDX ...

The FDA has granted Priority Review to Syndax’s supplemental New Drug Application (sNDA) seeking the approval of revumenib for the treatment of R/R mNPM1 AML. The sNDA is being reviewed under the ...

The FDA has granted Priority Review to Syndax's supplemental New Drug Application (sNDA) seeking the approval of revumenib for the treatment of R/R mNPM1 AML.

The FDA has granted Priority Review to Syndax’s supplemental New Drug Application (sNDA) seeking the approval of revumenib for the treatment of R/R mNPM1 AML.

Revuforj (revumenib) is an oral, first-in-class, selective menin inhibitor that is FDA approved for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene ...

Since Revuforj was approved, Syndax Pharmaceuticals has nearly doubled its staff to a total of around 300 and stood up a new commercial organization to market the drug. That transition has gone ...

Toripalimab has been approved in over 35 countries and regions including China, the US, and Europe. During the COVID-19 pandemic, Junshi Biosciences actively shouldered the social responsibilities of ...

Ongericimab is a recombinant humanized anti-PCSK9 monoclonal antibody injection independently developed by Junshi Biosciences. It was approved for marketing by the NMPA in October 2024.

Shares of Travere Therapeutics (Nasdaq: TVTX) fell 15.8% to $21.15 in after-hours trading, as the company revealed that the US Food and Drug Administration (FDA) has accepted its supplemental New Drug ...